# Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

> **NCT04339712** · PHASE2 · COMPLETED · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 102 (actual)

## Conditions studied

- COVID-19
- Virus Diseases
- Macrophage Activation Syndrome
- Corona Virus Infection

## Interventions

- **DRUG:** Anakinra
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04339712
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-02
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-01-08
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339712, "Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04339712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*